 |
6 Diseases |  |
10 Trials |
|
10 Trials |  |
617 News |  |
| «12345678» |
- || Clinical, Review, Journal: Calcitonin Gene-Related Peptide (CGRP) Antagonists: A comprehensive review of safety, efficacy and prescribing information. (Pubmed Central) - Jul 14, 2021
Head-to-head comparative studies with current guideline-recommended treatments are needed. However, CGRP antagonists are promising agents that present an alternative solution for patients living with migraine.
- | Ubrelvy (ubrogepant) / AbbVie, atogepant (AGN-241689) / AbbVie
Journal: Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries. (Pubmed Central) - Jul 3, 2021
ubrogepant and atogepant differentially inhibit the calcitonin gene-related peptide-dependent vasodilatory responses in intracranial arteries when compared to distal human coronary arteries. Also, both gepants are devoid of vasoconstrictive properties in human coronary arteries.
- || Review, Journal: Acute Treatment of Migraine: What has Changed in Pharmacotherapies? (Pubmed Central) - Jun 22, 2021
These 5-HT receptor agonists and CGRP receptor antagonists did not cause vasoconstriction, offering advantages over the current mainstay of specific acute migraine treatment. Overall, these new agents have expanded the available acute therapies for migraine treatment and will likely change the strategy with which we treat patients with migraine in the future.
- || Ubrelvy (ubrogepant) / AbbVie, Reyvow (lasmiditan) / Eli Lilly, Nurtec ODT (rimegepant ODT) / Portage
Retrospective data, Review, Journal: Ditans vs Gepants: A Systematic Review and Indirect Network Meta-Analysis for Comparative Analysis of Efficacy and Safety. (Pubmed Central) - Jun 22, 2021
All the newer drugs have shown significant improvement in the outcomes analyzed. Lasmiditan appears to be superior among the newer drugs in efficacy; however it has more adverse effects.
- | Retrospective data, Journal: Gepants for abortive treatment of migraine: A network meta-analysis. (Pubmed Central) - Jun 9, 2021
The most effective treatment of gepants for migraine might be olcegepant which were administrated transvenously. And all of gepants were safe for migraine treatment with single dose.
- Ubrelvy (ubrogepant) / AbbVie, Reyvow (lasmiditan) / Eli Lilly, Nurtec ODT (rimegepant ODT) / Portage
[VIRTUAL] Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments of migraine: Network meta-analysis findings on early onset of efficacy () - Jun 4, 2021 - Abstract #AHS2021AHS_390;
And all of gepants were safe for migraine treatment with single dose. Results of this NMA showed statistically significant higher efficacy for lasmiditan 100 and 200 mg, and comparable efficacy for lasmiditan 50mg, compared to both rimegepant and ubrogepant across the majority of pairwise comparisons of early-onset pain endpoints.
- Ubrelvy (ubrogepant) / AbbVie, Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] Real world efficacy, tolerability and safety of ubrogepant () - Jun 4, 2021 - Abstract #AHS2021AHS_384;
Adverse event rates were higher than reported in clinical trials. Further studies are needed to confirm these findings and to evaluate the long-term efficacy and safety of ubrogepant.
- Ubrelvy (ubrogepant) / AbbVie, Reyvow (lasmiditan) / Eli Lilly, Nurtec ODT (rimegepant ODT) / Portage
[VIRTUAL] Selection drivers for recently prescribed lasmiditan, ubrogepant, or rimegepant for the acute treatment of migraine: Results from an annual cross-sectional patient chart audit in the United States () - Jun 4, 2021 - Abstract #AHS2021AHS_369;
Among the newly approved acute treatments for migraine, lasmiditan may be used earlier in the treatment algorithm due to its mechanistic similarities to the standard-of-care triptan class. While the CGRP-mediated mechanism of action is also relevant in the decision to prescribe gepants, efficacy expectations appear more influential when selecting to prescribe rimegepant than ubrogepant.
- Reyvow (lasmiditan) / Eli Lilly, Nurtec ODT (rimegepant ODT) / Portage
[VIRTUAL] LasmiGepant: A case report of simultaneous administration of lasmiditan and rimegepant () - Jun 4, 2021 - Abstract #AHS2021AHS_366;
New treatments target specific migraine pathways with potentially less impact on unrelated neural activity or organ systems. As a result, no single, currently available treatment addresses the breadth of the pathophysiological cascade of migraine, nor demonstrates consistent efficacy across all patients.
- Ubrelvy (ubrogepant) / AbbVie
[VIRTUAL] Ubrogepant treatment when pain is mild increases the likelihood of achieving pain freedom in participants who treated migraine attacks of mild and moderate or severe pain () - Jun 4, 2021 - Abstract #AHS2021AHS_363;
P3
As a result, no single, currently available treatment addresses the breadth of the pathophysiological cascade of migraine, nor demonstrates consistent efficacy across all patients. These data indicate that treatment of migraine attacks with ubrogepant 50mg or 100mg when pain is mild versus moderate or severe significantly increases the odds of achieving pain freedom at 2 h. The findings in this subgroup, which treated attacks of both mild pain and moderate or severe pain, confirm the results that were observed in the overall trial population and further support the recommendation to treat early when pain is mild.
- Ubrelvy (ubrogepant) / AbbVie, Reyvow (lasmiditan) / Eli Lilly, Nurtec ODT (rimegepant ODT) / Portage
[VIRTUAL] Physician Assessment of Patients’ COVID-19 Risk and Impact on Lasmiditan, Ubrogepant, or Rimegepant Prescription Decisions: Analysis from a Cross-Sectional, Retrospective US Patient Chart Audit () - Jun 4, 2021 - Abstract #AHS2021AHS_316;
- Ubrelvy (ubrogepant) / AbbVie, Reyvow (lasmiditan) / Eli Lilly, Nurtec ODT (rimegepant ODT) / Portage
[VIRTUAL] Physician assessment of patients COVID-19 risk and impact on lasmiditan, ubrogepant, or rimegepant prescription decisions: Analysis from a cross-sectional, retrospective US patient chart audit () - Jun 4, 2021 - Abstract #AHS2021AHS_315;
For these higher risk patients, recent prescribing decisions of acute migraine therapies are more influenced by safety considerations and mechanism of action than physicians own familiarity with the therapy. With these considerations in mind, prescribing volume of the newly approved therapies did not differ, but triptans were less likely to be used as an alternative acute therapy.
- Ubrelvy (ubrogepant) / AbbVie
[VIRTUAL] A novel approach to defining success in the acute treatment of migraine: Demonstrating therapeutic benefit at 1 h post-dose in the pooled ACHIEVE I and ACHIEVE II trials () - Jun 4, 2021 - Abstract #AHS2021AHS_305;
The 1-h LCM estimates of therapeutic gain were approximately the same as those estimated at 2 h using the 2-h pain freedom endpoint. The LCM was a more sensitive predictor of treatment satisfaction at 24 h and better aligned with our clinical understanding of migraine as a symptom complex.
- Ubrelvy (ubrogepant) / AbbVie
[VIRTUAL] Ubrogepant was safe and well tolerated in the acute treatment of perimenstrual migraine () - Jun 4, 2021 - Abstract #AHS2021AHS_303;
The LCM was a more sensitive predictor of treatment satisfaction at 24 h and better aligned with our clinical understanding of migraine as a symptom complex. In this randomized 52-week extension trial, the efficacy of ubrogepant for the treatment of pmM was comparable to that observed for non-pmM.
- Ubrelvy (ubrogepant) / AbbVie
[VIRTUAL] A novel approach to defining success in the acute treatment of migraine: Pooled results from the ACHIEVE I and ACHIEVE II trials () - Jun 4, 2021 - Abstract #AHS2021AHS_302;
LCM also more sensitively predicted treatment satisfaction at 24 h and better aligned with our clinical understanding of migraine as a symptom complex. Compared with LCM classifications, the regulatory endpoint of 2hPF failed to capture a substantial proportion of patients satisfied with treatment.
- Ubrelvy (ubrogepant) / AbbVie, Reyvow (lasmiditan) / Eli Lilly, Nurtec ODT (rimegepant ODT) / Portage
[VIRTUAL] Novel acute therapies in the treatment of migraine: Impact of re-dosing on cost-utility outcomes () - Jun 4, 2021 - Abstract #AHS2021AHS_292;
When the impact of re-dosing is taken into account, rimegepant is associated with more favorable cost-effectiveness results versus usual care compared to ubrogepant and lasmiditan. These findings may be relevant for other cost-effectiveness analyses and may ultimately impact reimbursement policies and influence patient choice and access to more acute treatments for migraine.
- Trudhesa (dihydroergotamine mesylate intranasal) / Impel NeuroPharma
[VIRTUAL] Assessing the comparative efficacy of INP104 for acute treatment of migraine attacks: A matching-adjusted indirect comparison () - Jun 4, 2021 - Abstract #AHS2021AHS_262;
The SLR identified 15 unique randomized controlled trials that assessed rimegepant, ubrogepant and DHE nasal spray 4 mg/ml. INP104 was associated with greater reductions in pain and other migraine-related symptoms in an indirect comparison with gepants.
- sumatriptan succinate / Generic mfg.
[VIRTUAL] Identification of high-cost triptan and ergotamine-based acute therapies used for migraine in Medicaid 2019 () - Jun 4, 2021 - Abstract #AHS2021AHS_261;
However, 7.9% of Rx were for non-oral and/or branded triptans, and 0.5% for ergotamine-based products, which were associated with mean cost/unit of $94.16 (range $11.73-$330.59). Results highlight the potential high costs of triptans and ergotamine-based formulations that may be used in step therapy before trial of new oral migraine-specific acute therapies.
- Ubrelvy (ubrogepant) / AbbVie, Reyvow (lasmiditan) / Eli Lilly, Nurtec ODT (rimegepant ODT) / Portage
[VIRTUAL] Who receives novel acute treatments for migraine? () - Jun 4, 2021 - Abstract #AHS2021AHS_259;
This suggests that half of the patients had acute treatment failure/intolerance making it an equivalent driver for usage of novel acute treatments. This study may be biased by unique aspects associated with the earliest adopters of the emerging novel acute treatments of migraine.
- Ubrelvy (ubrogepant) / AbbVie, Reyvow (lasmiditan) / Eli Lilly, Nurtec ODT (rimegepant ODT) / Portage
[VIRTUAL] Rimegepant 75 mg, ubrogepant, and lasmiditan in the acute treatment of migraine applying the benefit-risk method of likelihood of being helped or harmed () - Jun 4, 2021 - Abstract #AHS2021AHS_252;
This study may be biased by unique aspects associated with the earliest adopters of the emerging novel acute treatments of migraine. In the acute treatment of migraine, all 3 active interventions were more effective than placebo, with acceptable safety profiles, but rimegepant 75 mg ODT had a better benefit-risk profile than all doses of ubrogepant and lasmiditan.
- || Ubrelvy (ubrogepant) / AbbVie, Qulipta (atogepant) / AbbVie
Enrollment closed, Adverse events: Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine (clinicaltrials.gov) - Jun 1, 2021
P1b, N=30, Active, not recruiting, Sponsor: Allergan
In the acute treatment of migraine, all 3 active interventions were more effective than placebo, with acceptable safety profiles, but rimegepant 75 mg ODT had a better benefit-risk profile than all doses of ubrogepant and lasmiditan. Not yet recruiting --> Active, not recruiting
- || Review, Journal: Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. (Pubmed Central) - May 28, 2021
Although all of these drugs seem highly promising for migraine treatment, their safety should be investigated in the long-term. Moreover, the exact mechanism(s) of action of these drugs need to be elucidated further, to increase both safety and efficacy and to increase the number of responders to the different treatments, so that all migraine patients can satisfactorily be treated.
- |||| Ubrelvy (ubrogepant) / AbbVie
Clinical, Real-world evidence: New Instagram post! Real-world efficacy, tolerability & safety of #ubrogepant by @ChiaChunChiang @KarissaArca Rachel Dunn, Marlene Girardo, Jaxon Quillen, @daviddodick @AmaalStarlingMD https://t.co/LwV3Bym2B4 #InstagramThursdays #HeadacheRFS #MedEd #neurotwitter #gepant #CGRP (Twitter) - May 27, 2021
- || Botox (onabotulinumtoxin A) / GSK, AbbVie
Review, Journal: Diagnosis and Management of Headache: A Review. (Pubmed Central) - May 22, 2021
Headache disorders affect approximately 90% of people during their lifetime. Among primary headache disorders, migraine is most debilitating and can be treated acutely with analgesics, nonsteroidal anti-inflammatory drugs, triptans, gepants, and lasmiditan.
- Ubrelvy (ubrogepant) / AbbVie, Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] COmbining UbRogepAnt and Preventives for MiGrainE (COURAGE) study using the migraine buddy application: A novel, entirely remote design for collecting real-world evidence () - May 16, 2021 - Abstract #AHS2021AHS_115;
This entirely remote design provides a unique opportunity to continue to understand treatment value and practice patterns while keeping patients and HCPs safe during the current COVID-19 pandemic. Interim findings suggest that ubrogepant is effective when used in combination with onabotA or a mAb; final data will help to inform practicing clinicians to optimize migraine treatment in their practices.
- ||| Ubrelvy (ubrogepant) / AbbVie
Clinical, P3 data, Journal: Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial. (Pubmed Central) - May 6, 2021
Interim findings suggest that ubrogepant is effective when used in combination with onabotA or a mAb; final data will help to inform practicing clinicians to optimize migraine treatment in their practices. Long-term intermittent use of ubrogepant 50 and 100 mg given as 1 or 2 doses per attack for the acute treatment of migraine was safe and well tolerated, as indicated by a low incidence of treatment-related TEAEs and SAEs and discontinuations due to adverse events in this 1-year trial.
- || Ubrelvy (ubrogepant) / AbbVie
Review, Journal: Ubrogepant in the Acute Management of Migraine: A Narrative Review. (Pubmed Central) - May 6, 2021
Adverse event rates were higher in the real-world population. Studies are needed to evaluate its long-term efficacy and safety, especially in the setting of co-administration with other CGRP modulating therapies such as the CGRP monoclonal antibodies.
- |||| Ubrelvy (ubrogepant) / AbbVie
Clinical: Although triptans have improved #migraine treatment, their tolerability may limit their utility in some individuals. In this @wileyneurology study, Dr. Peter Goadsby @petergoadsby assessed the efficacy of ubrogepant for acute treatment of migraine. https://t.co/aM06E06163 (Twitter) - Apr 18, 2021
- || Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ubrelvy (ubrogepant) / AbbVie
Awesome. The new drugs for migraine are amazing. I feel amazing with Emgality and Ubrelvy. Thanks @LillyPad and @allerganeye (Twitter) - Apr 14, 2021
- Trudhesa (dihydroergotamine mesylate intranasal) / Impel NeuroPharma
[VIRTUAL] Assessing the Comparative Efficacy of INP104 for Acute Treatment of Migraine Attacks- A Matching-Adjusted Indirect Comparison () - Apr 12, 2021 - Abstract #ISPOR2021ISPOR_1072;
Safety outcomes from the comparator trials observed either a single migraine or two migraines confounding the ability to make adequate comparisons to the STOP 301 study across multiple attacks over 24 and 52 weeks. CONCLUSIONS : INP104 was associated with greater reductions in pain and other migraine-related symptoms in an indirect comparison with gepants.
- || Ubrelvy (ubrogepant) / AbbVie, Qulipta (atogepant) / AbbVie
New P1 trial, Adverse events: Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine (clinicaltrials.gov) - Mar 25, 2021
P1b, N=30, Not yet recruiting, Sponsor: Allergan
- || Ubrelvy (ubrogepant) / AbbVie, Nurtec ODT (rimegepant ODT) / Portage
Clinical, Retrospective data, Review: Comparative Efficacy of Oral Calcitonin-Gene-Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis. (Pubmed Central) - Mar 23, 2021
CONCLUSIONS : INP104 was associated with greater reductions in pain and other migraine-related symptoms in an indirect comparison with gepants. CGRP antagonists are more effective than placebo against acute migraine; however, further studies are required to consider CGRP antagonists as standard first-line treatment for acute migraine instead of triptans, especially in patients with co-existing cardiovascular diseases.
- ||||| Ubrelvy (ubrogepant) / AbbVie
Clinical, Retrospective data: Efficacy of #ubrogepant based on prior exposure & response to #triptans: post hoc analysis #migraine #gepant Andrew M Blumenfeld, @petergoadsby @daviddodick Susan Hutchinson, Chengcheng Liu, Michelle Finnegan, Joel M Trugman, Armin Szegedi https://t.co/2eCsOOioRD (Twitter) - Mar 23, 2021
- Ubrelvy (ubrogepant) / AbbVie, Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] Real World Efficacy, Tolerability and Safety of Ubrogepant () - Mar 18, 2021 - Abstract #AAN2021AAN_2396;
Our study confirms and extends the efficacy profile and tolerability of ubrogepant in a real-world tertiary headache clinic, and identifies factors that may predict efficacy. Adverse event rates were higher than reported in clinical trials.
- Ubrelvy (ubrogepant) / AbbVie
[VIRTUAL] Ubrogepant Was Safe and Well Tolerated in the Acute Treatment of Perimenstrual Migraine () - Mar 18, 2021 - Abstract #AAN2021AAN_2395;
Adverse event rates were higher than reported in clinical trials. In this randomized 52-week extension trial, efficacy of ubrogepant for the treatment of pmMs was comparable to that observed for non-pmMs.
- Ubrelvy (ubrogepant) / AbbVie
[VIRTUAL] A Novel Approach to Defining Success in the Acute Treatment of Migraine: Pooled Results From the ACHIEVE I and ACHIEVE II Trials () - Mar 18, 2021 - Abstract #AAN2021AAN_1126;
The LCM approach yielded greater separation from placebo than the regulatory endpoint, 2hPF; more sensitively predicted treatment satisfaction at 24 hours; and better aligned with our clinical understanding of migraine as a symptom complex. Compared with LCM classifications, the regulatory endpoint of 2hPF failed to capture a substantial proportion of patients satisfied with treatment.
- Ubrelvy (ubrogepant) / AbbVie
[VIRTUAL] Improved Functionality, Satisfaction, and Global Impression of Change With Ubrogepant for the Acute Treatment of Migraine in Triptan Insufficient Responders () - Mar 18, 2021 - Abstract #AAN2021AAN_1125;
Compared with LCM classifications, the regulatory endpoint of 2hPF failed to capture a substantial proportion of patients satisfied with treatment. In people with migraine who are triptan insufficient responders, in comparison with the placebo arm, individuals treated with ubrogepant had favorable 2-hour outcomes, as measured by the FDS, patient satisfaction with medication, and PGIC.
- Ubrelvy (ubrogepant) / AbbVie
[VIRTUAL] Safety and Tolerability of Ubrogepant Within Various Demographic and Clinical Characteristic Subgroups () - Mar 18, 2021 - Abstract #AAN2021AAN_1056;
In people with migraine who are triptan insufficient responders, in comparison with the placebo arm, individuals treated with ubrogepant had favorable 2-hour outcomes, as measured by the FDS, patient satisfaction with medication, and PGIC. Safety and tolerability of ubrogepant were consistent within the various demographic and clinical characteristic subgroups, with no new safety signals identified.
- Ubrelvy (ubrogepant) / AbbVie
[VIRTUAL] Pharmacokinetics, Safety, and Tolerability of Ubrogepant for the Acute Treatment of Migraine Following Coadministration With Preventive Monoclonal Antibody Treatment () - Mar 18, 2021 - Abstract #AAN2021AAN_1026;
Ubrogepant PK was unchanged when coadministered with erenumab or galcanezumab. No safety concerns were identified.
- | Ubrelvy (ubrogepant) / AbbVie
Retrospective data, Journal: Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis. (Pubmed Central) - Mar 17, 2021
No safety concerns were identified. Ubrogepant is effective and safe for the treatment of acute migraine.
- | Ubrelvy (ubrogepant) / AbbVie, Reyvow (lasmiditan) / Eli Lilly, Nurtec ODT (rimegepant ODT) / Portage
Journal: Non-interacting, Non-opioid, and Non-barbiturate Containing Acute Medication Combinations in Headache: A Pilot Combinatorics Approach Based on DrugBank Database. (Pubmed Central) - Mar 9, 2021
We updated a list of acute medications based on the widely used Jefferson Headache Manual with novel abortive medications including ubrogepant, lasmiditan, and rimegepant...Most common elements in these combinations are ubrogepant, prochlorperazine, followed by tizanidine...Only two of the four-drug combinations do not yield some form of drug-drug interactions. This list of headaches abortive medications without drug-drug interactions is a useful tool for clinicians seeking to more effectively manage refractory headaches by implementing a rational polypharmacy.
- | Ubrelvy (ubrogepant) / AbbVie, Reyvow (lasmiditan) / Eli Lilly, Nurtec ODT (rimegepant ODT) / Portage
Journal: Pain Freedom at 2 to 8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant. (Pubmed Central) - Feb 27, 2021
This list of headaches abortive medications without drug-drug interactions is a useful tool for clinicians seeking to more effectively manage refractory headaches by implementing a rational polypharmacy. No abstract available
- || Ubrelvy (ubrogepant) / AbbVie
Clinical, Journal: Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials. (Pubmed Central) - Feb 21, 2021
P3
No abstract available These results further support the efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine.
- |||| Ubrelvy (ubrogepant) / AbbVie
Clinical, Adverse events: So excited this work is published!! Our study confirms the efficacy profile of ubrogepant in a tertiary headache clinic. We identifies factors that may predict efficacy. Adverse event rates were higher than reported in clinical trials. @KarissaArca @AmaalStarlingMD @daviddodick (Twitter) - Feb 8, 2021
- ||||| Ubrelvy (ubrogepant) / AbbVie
Clinical, Real-World Evidence: Real-world efficacy, tolerability, and safety of #ubrogepant @ChiaChunChiang @KarissaArca Rachel B. Dunn BS, Marlene E. Girardo MS, Jaxon K. Quillen BS, @daviddodick @AmaalStarlingMD https://t.co/u7WgqrkmVh #CGRP #migraine (Twitter) - Feb 8, 2021
- || Ubrelvy (ubrogepant) / AbbVie
Clinical, Review, Journal: Ubrogepant to Treat Acute Migraine in Adults. (Pubmed Central) - Feb 3, 2021
In summary, Ubrogepant has good tolerability and an overall favorable safety profile. It appears to hold promise for the acute treatment of migraines with or without aura in adults.
- | Journal: Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? (Pubmed Central) - Jan 29, 2021
They will likely have no cardiovascular warnings. Because of the particular benefit gepants may represent for these groups of patients, specific studies in patients with medication overuse headache, as well as those with comorbid cardiovascular diseases, would be of considerable interest.
- | Botox (onabotulinumtoxin A) / GSK, AbbVie
Journal: Drugs for Migraine. (Pubmed Central) - Jan 23, 2021
Because of the particular benefit gepants may represent for these groups of patients, specific studies in patients with medication overuse headache, as well as those with comorbid cardiovascular diseases, would be of considerable interest. No abstract available
- | Ubrelvy (ubrogepant) / AbbVie
Journal: Correction to "Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor". (Pubmed Central) - Dec 29, 2020
No abstract available No abstract available
- | Journal: Novel synthetic treatment options for migraine. (Pubmed Central) - Dec 29, 2020
On the contrary, the new generation of gepants showed a placebo-like tolerability profile and the absence of a specific pattern of side effects. Future studies on lasmiditan and gepants with respect to established effective comparators are mandatory to support phase III results and to help clinicians to balance the benefit/risk profiles of the various acute and preventive medications.